Asthma

A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.

This review compares the clinical and real-world outcomes of drugs such as mepolizumab versus drugs such as benralizumab for severe eosinophilic asthma.

Patients who underwent FESS required less medication and had fewer allergy and pulmonology visits than patients who did not have surgery.

The literature review suggests allergen immunotherapy can effectively treat allergic asthma and prevent its development in patients with allergic rhinitis.

The latest episode of Lungcast explores the evolving field of pulmonary imaging technology and the transformative impact of artificial intelligence.

Wilson details how her team plans to develop risk assessment models to estimate respiratory viral infection risk reductions for interventions in elementary schools.

This approval expands the drug’s age range and follows recent positive phase 3 findings on dupilumab treatment for patients aged 12 to 17 with CRSwNP.

These data on depemokimab, a long-acting asthma treatment, suggest the medication reduces serious attacks by more than half and strongly reduces asthma exacerbations.

In this Lungcast episode, Mora and Sadeameli highlight Asthma Action Plans as well as Asthma Peak Weak considerations for children in the new school year.

Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.

These data highlighted new findings on the experiences of children aged 6 to 11 with uncontrolled type 2 asthma treated with dupilumab.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.

These findings also highlighted the necessity of identifying the clinically relevant comorbidities of asthma and allergic rhinitis in a proactive manner.

The panel offers their final recommendations for physicians managing patients with asthma.

The panel discusses the biologic drugs approved for use in children with asthma, including omalizumab, dupilumab, mepolizumab, and the recently approved benralizumab. They share their preferences among these options for improving lung function in pediatric patients.

Robert Sporter, MD, discusses the initial conversations he has with pediatric patients and their parents when considering biologic therapies, addressing the risks associated with not treating the condition, such as compromised lung function and increased steroid use. He emphasizes the importance of communicating a comprehensive treatment plan, including contingencies for cases where a particular therapy may not be effective.

Shahzad Mustafa, MD, examines the pediatric atopic march, a phenomenon characterized by the sequential development of wheezing, asthma, and food allergies in children, discussing the progression and interrelationship of these conditions. He also explores the potential benefits of early intervention with medications in managing these conditions in pediatric patients.

Robert Sporter, MD, explores the differences in treatment approaches between adult and pediatric populations, focusing on allergy-based asthma treatments such as allergen immunotherapy and biologics, and their specific applications in managing asthma in children.

Medical experts discuss eligibility criteria for biologic therapies, noting that biologics can be used for other allergies and in patients with comorbidities, highlighting the potential for these targeted treatments to benefit a broad age range of patients.

Sande Okelo, MD, leads a discussion on the updates in the GINA 2021 report regarding difficult-to-treat and severe asthma, as well as considerations for GINA Step 4 and 5 treatment approaches.

The expert panel discusses the use of biologics in treating asthma, explaining their mechanisms of action, differences, and target populations, while also examining trends in long-term efficacy and safety for patients with severe or uncontrolled asthma.

The key opinion leaders explore the utilization of biomarkers in guiding the treatment of severe or uncontrolled asthma, discussing the specific role of eosinophils in informing therapeutic decision-making for patients with challenging asthma cases.

Sande Okelo, MD, outlines the factors that contribute to the overuse of oral corticosteroids (OCS), such as nonadherence, poor inhaler technique, inappropriate prescription, and comorbidities, while also discussing strategies to limit OCS overuse and acknowledging that undertreatment can also be a significant issue.

Lovinsky-Desir joins Lungcast on World Asthma Day to discuss community-specific burdens of disease, and emerging strategies to manage it.

Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.